Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1984-11-15
|
| pubmed:abstractText |
Bevantolol hydrochloride, a new beta-adrenoceptor antagonist, has been shown to be cardioselective in animals. To evaluate its selectivity in humans, a double-blind, crossover study was conducted in 8 asthmatics. Following a single oral dose of placebo, bevantolol 75 or 150 mg or propranolol hydrochloride 40 mg, forced expiratory volume in 1 second (FEV1), heart rate, blood pressure and skeletal muscle tremor were measured before and after 4 increasing intravenous doses of terbutaline sulfate to establish terbutaline dose-response curves. The FEV1 decreased after all active treatments. During terbutaline infusions there was an increase in FEV1 after both bevantolol doses and placebo. The terbutaline dose-response curve after bevantolol shifted to the right, however. After propranolol, there was no increase in FEV1 during terbutaline stimulation. Heart rate and skeletal muscle tremor showed a similar pattern during the experiment. In dosages that have previously been shown to produce at least the same degree of blockade of exercise-induced tachycardia, bevantolol has less influence on terbutaline-induced bronchodilation, heart rate increase and skeletal muscle tremor than did propranolol. Thus bevantolol has relative beta 1-adrenoceptor antagonist selectivity. Drawing upon the results of a previous study in the same patients, we believe bevantolol, atenolol and metoprolol have similar beta 1-selectivity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0277-0008
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
4
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
205-10
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:6148733-Adrenergic beta-Antagonists,
pubmed-meshheading:6148733-Adult,
pubmed-meshheading:6148733-Aged,
pubmed-meshheading:6148733-Asthma,
pubmed-meshheading:6148733-Blood Pressure,
pubmed-meshheading:6148733-Bronchi,
pubmed-meshheading:6148733-Dose-Response Relationship, Drug,
pubmed-meshheading:6148733-Double-Blind Method,
pubmed-meshheading:6148733-Female,
pubmed-meshheading:6148733-Forced Expiratory Volume,
pubmed-meshheading:6148733-Heart Rate,
pubmed-meshheading:6148733-Humans,
pubmed-meshheading:6148733-Male,
pubmed-meshheading:6148733-Middle Aged,
pubmed-meshheading:6148733-Muscles,
pubmed-meshheading:6148733-Propanolamines,
pubmed-meshheading:6148733-Propranolol,
pubmed-meshheading:6148733-Random Allocation
|
| pubmed:articleTitle |
Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|